---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-21-023087"
form_type: "8-K"
ticker: "MTNB"
cik: "0001582554"
company_name: "Matinas BioPharma Holdings, Inc."
filed_at: "2021-09-20T23:59:59+00:00"
generated_at: "2026-06-29T02:39:09.703418+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Matinas BioPharma nominates Kathryn Penkus Corzo to board; LePore not standing for re-election

## Summary
- Patrick LePore will not stand for re-election at the 2021 Annual Meeting on November 1, 2021.
- Kathryn Penkus Corzo nominated to stand for election to the Board at the same meeting.
- Corzo is a partner at Takeda Ventures and formerly Head of Oncology Cell Therapy Development at Takeda.
- LePore served as Vice Chairman and was thanked for his three years of service.

## SEC filing metadata
- accession: 0001493152-21-023087
- form_type: 8-K
- ticker: MTNB
- cik: 0001582554
- company_name: Matinas BioPharma Holdings, Inc.
- filed_at: 2021-09-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582554/000149315221023087/0001493152-21-023087-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582554/000149315221023087/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-21-023087
- JSON: https://secwatch.observer/filing/0001493152-21-023087.json
- Plain text: https://secwatch.observer/filing/0001493152-21-023087.txt

## Key facts
- Executive change
  Patrick LePore resigned as Director at Matinas BioPharma Holdings, Inc..
  - Action: resigned
  - Role: Director
  source text: On September 17, 2021, director Patrick LePore informed the Board of Directors (the “Board”) of Matinas BioPharma Holdings, Inc. (the “Company”) that he will not stand for re-election to the Board at the upcoming annual meeting of stockholders, which will be held on November 1, 2021 (the “Annual Meeting”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582554/000149315221023087/0001493152-21-023087-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.